Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study

Giuseppe Derosa,1–3 Angela D’Angelo,2 Pamela Maffioli1 1Center of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 2Laboratory of Molecular Medicine, University of Pav...

Full description

Bibliographic Details
Main Authors: Derosa G, D'Angelo A, Maffioli P
Format: Article
Language:English
Published: Dove Medical Press 2019-10-01
Series:Drug Design, Development and Therapy
Subjects:
Online Access:https://www.dovepress.com/coenzyme-q10-liquid-supplementation-in-dyslipidemic-subjects-with-stat-peer-reviewed-article-DDDT
id doaj-6ca9dba181d340b89a570f1291e62dec
record_format Article
spelling doaj-6ca9dba181d340b89a570f1291e62dec2020-11-25T01:50:29ZengDove Medical PressDrug Design, Development and Therapy1177-88812019-10-01Volume 133647365549231Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled studyDerosa GD'Angelo AMaffioli PGiuseppe Derosa,1–3 Angela D’Angelo,2 Pamela Maffioli1 1Center of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 2Laboratory of Molecular Medicine, University of Pavia, Pavia, Italy; 3Center for Prevention, Surveillance, Diagnosis and Treatment of Rare Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, ItalyCorrespondence: Giuseppe DerosaDepartment of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, P.le C. Golgi, 2, Pavia 27100, ItalyTel +39 038 252 6217Fax +39 038 252 6259Email giuseppe.derosa@unipv.itIntroduction: Statin-associated myalgia occurs in about 1–3% of patients in the medical literature. Plasma CoQ10 levels are reduced in patients undergoing statin.Objective: The primary outcome was the detection of clinical symptoms and the perception of pain evaluated throughout specific questionnaires. The secondary outcome was the variation in lipid profile and the variation in safety parameters.Methods: We enrolled 60 Caucasian patients, intolerant to statins. During the run-in period, patients underwent a 1-month wash-out period during which statins were stopped. At the end of the wash-out period, if CPK and/or transaminases returned within an acceptable range, statins were re-introduced at half of the previously taken dose. After one month, patients were randomized to take either a liquid CoQ10 supplement or a placebo for three months at 100 mg/day.Results: The Clinical Index Score for myalgia assessment was lower after 3 months with CoQ10, while it did not change with the placebo. The VAS score was lower after 3 months of CoQ10 supplementation, while no variation was recorded with the placebo. In the group treated with the dietary supplement, CoQ10 plasma concentrations were inversely correlated with CPK levels, Clinical Index Score absolute values, and VAS.Conclusion: The addition of CoQ10 with half dosage statin in patients with previous intolerance to statins improves the perception of clinical symptoms such as asthenia, myalgia or pain.Keywords: coenzyme Q10, myalgia, statinshttps://www.dovepress.com/coenzyme-q10-liquid-supplementation-in-dyslipidemic-subjects-with-stat-peer-reviewed-article-DDDTCoenzyme Q10MyalgiaStatins
collection DOAJ
language English
format Article
sources DOAJ
author Derosa G
D'Angelo A
Maffioli P
spellingShingle Derosa G
D'Angelo A
Maffioli P
Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study
Drug Design, Development and Therapy
Coenzyme Q10
Myalgia
Statins
author_facet Derosa G
D'Angelo A
Maffioli P
author_sort Derosa G
title Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study
title_short Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study
title_full Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study
title_fullStr Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study
title_full_unstemmed Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study
title_sort coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study
publisher Dove Medical Press
series Drug Design, Development and Therapy
issn 1177-8881
publishDate 2019-10-01
description Giuseppe Derosa,1–3 Angela D’Angelo,2 Pamela Maffioli1 1Center of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 2Laboratory of Molecular Medicine, University of Pavia, Pavia, Italy; 3Center for Prevention, Surveillance, Diagnosis and Treatment of Rare Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, ItalyCorrespondence: Giuseppe DerosaDepartment of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, P.le C. Golgi, 2, Pavia 27100, ItalyTel +39 038 252 6217Fax +39 038 252 6259Email giuseppe.derosa@unipv.itIntroduction: Statin-associated myalgia occurs in about 1–3% of patients in the medical literature. Plasma CoQ10 levels are reduced in patients undergoing statin.Objective: The primary outcome was the detection of clinical symptoms and the perception of pain evaluated throughout specific questionnaires. The secondary outcome was the variation in lipid profile and the variation in safety parameters.Methods: We enrolled 60 Caucasian patients, intolerant to statins. During the run-in period, patients underwent a 1-month wash-out period during which statins were stopped. At the end of the wash-out period, if CPK and/or transaminases returned within an acceptable range, statins were re-introduced at half of the previously taken dose. After one month, patients were randomized to take either a liquid CoQ10 supplement or a placebo for three months at 100 mg/day.Results: The Clinical Index Score for myalgia assessment was lower after 3 months with CoQ10, while it did not change with the placebo. The VAS score was lower after 3 months of CoQ10 supplementation, while no variation was recorded with the placebo. In the group treated with the dietary supplement, CoQ10 plasma concentrations were inversely correlated with CPK levels, Clinical Index Score absolute values, and VAS.Conclusion: The addition of CoQ10 with half dosage statin in patients with previous intolerance to statins improves the perception of clinical symptoms such as asthenia, myalgia or pain.Keywords: coenzyme Q10, myalgia, statins
topic Coenzyme Q10
Myalgia
Statins
url https://www.dovepress.com/coenzyme-q10-liquid-supplementation-in-dyslipidemic-subjects-with-stat-peer-reviewed-article-DDDT
work_keys_str_mv AT derosag coenzymeq10liquidsupplementationindyslipidemicsubjectswithstatinrelatedclinicalsymptomsadoubleblindrandomizedplacebocontrolledstudy
AT dangeloa coenzymeq10liquidsupplementationindyslipidemicsubjectswithstatinrelatedclinicalsymptomsadoubleblindrandomizedplacebocontrolledstudy
AT maffiolip coenzymeq10liquidsupplementationindyslipidemicsubjectswithstatinrelatedclinicalsymptomsadoubleblindrandomizedplacebocontrolledstudy
_version_ 1725001729731198976